Mois : septembre 2020

IACM-Bulletin du 07 Septembre 2020

IACM-Bulletin du 07 Septembre 2020 Israël: La réduction des prix du cannabis médical et le CBD n'est plus un stupéfiant Science/Homme: La consommation fréquente de cannabis réduit la consommation d'opioïdes Science/Homme: La consommation de cannabis est associée à une réduction du risque de diabète chez les personnes atteintes d'hépatite C Science/Homme: La consommation de cannabis réduit l'hospitalisation des patients drépanocytaires En bref Un coup d'œil sur le passé Israël: La réduction des prix du cannabis médical et le CBD n'est plus un stupéfiant Le ministre de la Santé Yuli Edelstein et son adjoint [...]

Lire la suite

What Can We Learn About Schizophrenia From Studying the Human Model, Drug-Induced Psychosis ?, Robin M. Murray et al., 2013

What Can We Learn About Schizophrenia From Studying the Human Model, Drug-Induced Psychosis ? Robin M. Murray, Alessandra Paparelli, Paul D. Morrison, Arianna Marconi, and Marta Di Forti American Journal of Medical Genetics, Part B, 2013, 162B, 661–670. Doi : 10.1002/ajmg.b.32177   When drug-induced psychoses were first identified in the mid- 20th century, schizophrenia was considered a discrete disease with a likely genetic cause. Consequently, drug-induced psychoses were not considered central to understanding schizophrenia as they were thought to be phenocopies rather than examples of the illness secondary to a particular known cause. However, now that we know that schizophrenia is a clinical syndrome with [...]

Lire la suite

Cannabinoids : Extraction Methods, Analysis and Physicochemical Characterization, Cristina Lujan RAMIREZ et al., 2019, ,

Cannabinoids : Extraction Methods, Analysis and Physicochemical Characterization Cristina Lujan RAMIREZ, Maria Alejandra FANOVICH, Maria Sandra CHURIO. Studies in Natural Products Chemistry, Chapter 4, 2019, Volume 61, 143-173 (1-44). Doi : 10.1016/B978-0-444-64183-0.00004-X ABSTRACT : A new paradigm has been established in the application of cannabinoids in the last decade. The growing accessibility to different types of Cannabis products and the rise in concern about their health benefits have provoked a rapid expansion of the research interests in phytocannabinoids with promising pharmacological properties. The characterization of the diverse chemotypes of Cannabis sativa, the elucidation of their various structures, and quantification of cannabinoids in the complex [...]

Lire la suite

The association between cannabis use and mood disorders : A longitudinal study, Daniel Feingold et al., 2015

The association between cannabis use and mood disorders : A longitudinal study Daniel Feingold, Mark Weiser, Jürgen Rehme, Shaul Lev-Ran Journal of Affective Disorders, 2015, 172, 211–218. doi : 10.1016/j.jad.2014.10.006   a b s t r a c t Background : The association between cannabis use and mood disorders is well documented, yet evidence regarding causality is conflicting. This study explored the association between cannabis use, major depressive disorder (MDD) and bipolar disorder (BPD) in a 3-year prospective study. Methods : Data was drawn from waves 1 and 2 of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). MDD and BPD were controlled at baseline [...]

Lire la suite

Cancer, Cannabis, and the Search for Relief, Marcin Chwistek, 2019

Cancer, Cannabis, and the Search for Relief Marcin Chwistek JNCCN—Journal of the National Comprehensive Cancer Network, 2019, Volume 17, Issue 9, 1142-1144. doi : 10.6004/jnccn.2019.7347   “How about medical marijuana?” is a common and often challenging question in oncology clinics today. It is easy to see why. Answering the question is fraught with clinical, legal, and administrative uncertainties. We all want to give patients the best advice, but not much about medical cannabis seems straightforward today. Whatever answer we provide can feel unsatisfactory to patients or ourselves. Answering clinical questions through high-quality research will take many years. And significant political power will be needed to [...]

Lire la suite

A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers, Johannes G. Ramaekers et al., 2020,

A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers Johannes G. Ramaekers, Nadia Hutten, Natasha L. Mason, Patrick Dolder1, Eef L. Theunissen, Friederike Holze, Matthias E. Liechti, Amanda Feilding and Kim P.C. Kuypers Journal of Psychopharmacology, 2020, 1–8. doi : 10.1177/026988112094093   Abstract Background : Lysergic acid diethylamide (LSD) is an ergot alkaloid derivative with psychedelic properties that has been implicated in the management of persistent pain. Clinical studies in the 1960s and 1970s have demonstrated profound analgesic effects of full doses of LSD in terminally ill patients, but this line of research evaporated after LSD was scheduled worldwide. Aim : The present [...]

Lire la suite